Researcher guests Alessia Roma, Lawrence D. Goodridge, and Paul A. Spagnuolo from the University of Guelph discuss the aggressive nature of acute myeloid leukemia (AML) and the potential of reductive carboxylation of glutamine as a target for novel therapies to improve patient outcomes. They highlight the importance of understanding metabolic vulnerabilities in AML and the advancements in targeting these vulnerabilities in drug development.